• Home
  • Politics
  • Health
  • World
  • Business
  • Finance
  • Tech
  • More
    • Sports
    • Entertainment
    • Lifestyle
What's Hot

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

May 29, 2025

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Saturday, May 31
Patriot Now NewsPatriot Now News
  • Home
  • Politics

    Security video shows brazen sexual assault of California woman by homeless man

    October 24, 2023

    Woman makes disturbing discovery after her boyfriend chases away home intruder who stabbed him

    October 24, 2023

    Poll finds Americans overwhelmingly support Israel’s war on Hamas, but younger Americans defend Hamas

    October 24, 2023

    Off-duty pilot charged with 83 counts of attempted murder after allegedly trying to shut off engines midflight on Alaska Airlines

    October 23, 2023

    Leaked audio of Shelia Jackson Lee abusively cursing staffer

    October 22, 2023
  • Health

    Disparities In Cataract Care Are A Sorry Sight

    October 16, 2023

    Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

    October 16, 2023

    Long-term steroid use should be a last resort

    October 16, 2023

    Rite Aid Files For Bankruptcy With More ‘Underperforming Stores’ To Close

    October 16, 2023

    Who’s Still Dying From Complications Related To Covid-19?

    October 16, 2023
  • World

    New York Democrat Dan Goldman Accuses ‘Conservatives in the South’ of Holding Rallies with ‘Swastikas’

    October 13, 2023

    IDF Ret. Major General Describes Rushing to Save Son, Granddaughter During Hamas Invasion

    October 13, 2023

    Black Lives Matter Group Deletes Tweet Showing Support for Hamas 

    October 13, 2023

    AOC Denounces NYC Rally Cheering Hamas Terrorism: ‘Unacceptable’

    October 13, 2023

    L.A. Prosecutors Call Out Soros-Backed Gascón for Silence on Israel

    October 13, 2023
  • Business

    EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

    May 29, 2025

    ‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

    May 29, 2025

    DeSantis Signs Bill Making Gold And Silver Legal Tender

    May 28, 2025

    John Deere Announces $20 Billion Plan To Build Up American Manufacturing

    May 28, 2025

    EV Startup Promised To Cut China Ties — Then Reportedly Shared US Data Anyway

    May 27, 2025
  • Finance

    Ending China’s De Minimis Exception Brings 3 Benefits for Americans

    April 17, 2025

    The Trump Tariff Shock Should Push Indonesia to Reform Its Economy

    April 17, 2025

    Tariff Talks an Opportunity to Reinvigorate the Japan-US Alliance

    April 17, 2025

    How China’s Companies Are Responding to the US Trade War

    April 16, 2025

    The US Flip-flop Over H20 Chip Restrictions 

    April 16, 2025
  • Tech

    Cruz Confronts Zuckerberg on Pointless Warning for Child Porn Searches

    February 2, 2024

    FTX Abandons Plans to Relaunch Crypto Exchange, Commits to Full Repayment of Customers and Creditors

    February 2, 2024

    Elon Musk Proposes Tesla Reincorporates in Texas After Delaware Judge Voids Pay Package

    February 2, 2024

    Tesla’s Elon Musk Tops Disney’s Bob Iger as Most Overrated Chief Executive

    February 2, 2024

    Mark Zuckerberg’s Wealth Grew $84 Billion in 2023 as Pedophiles Target Children on Facebook, Instagram

    February 2, 2024
  • More
    • Sports
    • Entertainment
    • Lifestyle
Patriot Now NewsPatriot Now News
Home»Health»Lawsuits To Block Medicare Drug Price Negotiations Are Very Unpopular
Health

Lawsuits To Block Medicare Drug Price Negotiations Are Very Unpopular

October 1, 2023No Comments5 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Lawsuits To Block Medicare Drug Price Negotiations Are Very Unpopular
Share
Facebook Twitter LinkedIn Pinterest Email

President Joe Biden signs the Inflation Reduction Act of 2022 into law during a ceremony in the … [+] State Dining Room of the White House in Washington, DC, on August 16, 2022. Legal challenges to the IRA’s drug pricing provisions have been filed by the Chamber of Commerce and a number of pharmaceutical manufacturers. (Photo by MANDEL NGAN / AFP) (Photo by MANDEL NGAN/AFP via Getty Images)

AFP via Getty Images

The Inflation Reduction Act’s prescription drug pricing provisions include price negotiations between Medicare and drug manufacturers for a limited subset of pharmaceuticals. Thus far, this particular stipulation in the law is subject to eight legal challenges. Six manufacturers and two industry groups have filed suits seeking to declare drug price negotiations unconstitutional or unenforceable.

Yet it’s the IRA’s drug pricing components that are viewed very favorably by voters on both sides of the political spectrum. Accordingly, the industry’s lawsuits to block Medicare from price negotiations are quite unpopular among constituents.

While some Republicans have talked about repealing the IRA, they’ve generally focused their attention on sections of the $737 billion bill which include green energy, climate change and bolstering Internal Revenue Service enforcement. They haven’t spoken as much about the IRA’s provisions aimed at lowering patient out-of-pocket spending on prescription drugs by seniors and disabled people enrolled in Medicare. There’s perhaps good reason for this, as it’s precisely these parts of the legislation that are resoundingly popular.

A national survey released two weeks ago shows that Americans overwhelmingly–by more than a five-to-one margin–oppose the pharmaceutical industry’s lawsuits attempting to impede Medicare from directly negotiating lower prescription drug prices. What may concern the industry is that by an almost four-to-one margin voters don’t believe the argument that lower negotiated prices will eventually lead to fewer new treatments.

It’s not as if the pharmaceutical industry’s line of reasoning is completely bogus. The IRA may reduce investment in research and development, which in turn could lead to fewer drug approvals down the road. The Congressional Budget Office estimated that the IRA’s drug price negotiations would result in “less innovation,” specifically two fewer drugs being brought to market over the next decade, five fewer pharmaceuticals in the following 10 year period, and eight fewer drugs in the decade after that. Furthermore, other estimates suggest steeper declines in approvals over time.

But it appears that this is not something the average person in the street takes note of. Nor do most people realize that high out-of-pocket expenses for consumers aren’t solely the result of drug company policies. Certain actors in the drug supply chain, including pharmacy benefit managers, also play a role. However, a nuanced discussion of drug pricing doesn’t resonate.

What folks want is immediate relief from the ever-increasing out-of-pocket costs on prescription drugs. And they see the drug industry as the number one culprit.

Seen in this light, only 18% of Americans view the pharmaceutical industry favorably. That’s a new record low in favorability ratings.

Moreover, according to the survey the legal actions taken to oppose what Medicare is implementing seem to be reinforcing the negative attitude many Americans have. Poll results show that the respondents who viewed drug firms unfavorably increased from half to two thirds upon hearing about the lawsuits.

Politically, there’s an electoral risk here for Republican incumbents and challengers alike, which may explain the reluctance of some legislators to side with the drug industry.

But there’s also a problem for the pharmaceutical industry itself in terms of its public image. Broader support among ordinary citizens can help shape what lawmakers do in Washington DC, to boost the industry’s fortunes, for example, through tax incentives, research subsidies and improvement in access to biopharmaceuticals provided under the government programs, Medicare and Medicaid.

On the other hand, a wary or critical public could harm pharma’s standing among legislators on both sides of the aisle. Consider, for instance, that among Democrats and even a number of Republicans there is backing for measures that could be more impactful than the IRA.

House Democrats want to expand the scope of the IRA by increasing the numbers of drugs eligible for negotiation while extending the applicability of negotiated prices to employer-sponsored health plans and those offered on the state insurance marketplaces.

And, while in office as President the now likely presidential nominee of the Republican Party, Donald Trump, issued executive orders that would have pegged the prices of certain pharmaceuticals to the average or lowest price among our peers. International price referencing may pose a greater threat to the pharmaceutical industry than any provision included in the IRA. As a reminder, Trump has repeatedly criticized the industry for “unfair pricing” behavior and “getting away with murder.”

In the end, the pharmaceutical industry must ask itself whether the fight against IRA drug price negotiations is worth pursuing. From a judicial perspective it may not be, as last week’s rejection by a U.S. District Court in Ohio of the Chamber of Commerce’s request for a court injunction suggests. Perhaps most concerning from the industry’s viewpoint is the fact that the judge ruled the “law established in the Sixth Circuit and beyond is clear: Participation in Medicare, no matter how vital it may be to a business model, is a completely voluntary choice.” It’s possible that this kind of legal reasoning becomes a recurring theme in judges’ decisions on the cases brought before them.

In addition, the litigation may backfire. It could cause an already adversarial Congress to become more so, on both sides of the aisle, as constituents voice their displeasure. For an industry that already has a public relations problem the suits challenging the legality of Medicare drug price negotiations may not be a hill it wants to die on.

See also  Teens Who Vape Want To Quit. They Just Don’t Know How.
Block Drug Lawsuits Medicare Negotiations Price Unpopular
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Walmart Announces Tariff-Driven Price Hike After Announcing Billions In Profit

May 15, 2025

Amazon Reportedly Floats Plan To Show Tariff Price Increases To Shoppers — Karoline Leavitt Calls It ‘Hostile’ Move

April 29, 2025

Southeast Asian Governments Seek Negotiations Over Trump Tariffs

April 8, 2025

What Are The Consequences Of A Drug Possession Conviction?

March 19, 2025
Add A Comment

Leave A Reply Cancel Reply

Top Posts

Kevin McCarthy on JCPA Media Cartel Bill: ‘It’s Dead in the House’

June 12, 2023

PMD Clean Redvolution Review: Tried and Tested 2024

June 6, 2024

Lisa Vanderpump’s Husband Fighting $1 Million Lawsuit Brought By PUMP’s Ex-Landlord, Denies Owing Unpaid Rent

September 16, 2023

‘The View’ Host Joy Behar Says She’s ‘Turned On’ By Joe Biden’s Angry Outbursts

July 13, 2023
Don't Miss

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

Business May 29, 2025

Consumers’ Research issued a “Woke Alert” on Thursday warning American shoppers that three European companies…

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025

John Deere Announces $20 Billion Plan To Build Up American Manufacturing

May 28, 2025
About
About

This is your World, Tech, Health, Entertainment and Sports website. We provide the latest breaking news straight from the News industry.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest
Categories
  • Business (4,136)
  • Entertainment (4,220)
  • Finance (3,202)
  • Health (1,938)
  • Lifestyle (1,645)
  • Politics (3,084)
  • Sports (4,036)
  • Tech (2,006)
  • Uncategorized (4)
  • World (3,944)
Our Picks

Joe Biden: “When I Left the Senate, I Was Able to Convince Strom Thurmond to Vote for the Voting Rights Act” – Thurmond Voted Against It (VIDEO) | The Gateway Pundit

October 2, 2023

80 Funny Summer Quotes for Laughs, Stress Relief and a Hilarious Hot Season

April 25, 2025

‘Unacceptable’: GOP Reps, Defense Experts Raise Red Flags Over Pentagon’s Reliance On China For Critical Minerals

February 14, 2023
Popular Posts

EXCLUSIVE: ‘The Man She Is Today’: European Companies Accused Of ‘Importing’ Woke Ideology

May 29, 2025

‘The Economy Is On Fire!’: Kevin O’Leary Drops Fact Check On CNN Panelists Railing Against Trump’s Economy

May 29, 2025

DeSantis Signs Bill Making Gold And Silver Legal Tender

May 28, 2025
© 2025 Patriotnownews.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.